Journal article
Cardiac biomarkers and haemodynamically significant patent ductus arteriosus in preterm infants
Early human development, Vol.105, pp.41-47
02/2017
DOI: 10.1016/j.earlhumdev.2016.12.007
PMID: 27998626
Abstract
Accurately defining haemodynamically significant patent ductus arteriosus (PDA) in preterm infants who are at risk of PDA related morbidities are active areas of neonatal research. Natriuretic peptides are cardiac hormones that respond to volume and pressure loading, with elevated plasma levels found in infants with PDA. In the preterm neonatal setting, studies to date have predominantly investigated the ability of these biomarkers to discriminate between infants with and without a PDA at various postnatal ages. Their clinical utility has therefore been exclusively evaluated as a method of triaging cases of suspected hsPDA to decrease the need for echocardiograms, and to monitor treatment response. Biomarkers are yet to be robustly investigated for their ability to predict important PDA associated morbidities. In this review, we examine the most recent literature to date on the use of biomarkers in the management of PDA.
Details
- Title: Subtitle
- Cardiac biomarkers and haemodynamically significant patent ductus arteriosus in preterm infants
- Creators
- Dany E Weisz - Department of Newborn and Developmental Paediatrics, Sunnybrook Health Sciences Centre, Toronto, CanadaPatrick J McNamara - Department of Paediatrics, University of Toronto, Toronto, CanadaAfif El-Khuffash - Department of Neonatology, The Rotunda Hospital, Dublin, Ireland
- Resource Type
- Journal article
- Publication Details
- Early human development, Vol.105, pp.41-47
- Publisher
- Elsevier B.V
- DOI
- 10.1016/j.earlhumdev.2016.12.007
- PMID
- 27998626
- ISSN
- 0378-3782
- eISSN
- 1872-6232
- Language
- English
- Date published
- 02/2017
- Academic Unit
- Stead Family Department of Pediatrics; Neonatology; Internal Medicine
- Record Identifier
- 9984093328102771
Metrics
13 Record Views